The goal of this eHealth Source™ activity is to educate clinicians on atopic dermatitis pathoetiology, best practices in patient evaluations, and the clinical profiles of treatment options for moderate-to-severe disease, including a biologic therapy recently approved by the US Food and Drug Administration (FDA). With the overall goal of improving outcomes for patients with moderate-to-severe atopic dermatitis, this educational activity integrates published clinical data and the experience of expert faculty to provide actionable recommendations on individualizing care and improving patient-clinician communication.